KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) EBT (2016 - 2025)

Historic EBT for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q3 2025 value amounting to $239.0 million.

  • Alnylam Pharmaceuticals' EBT rose 31991.75% to $239.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$31.9 million, marking a year-over-year increase of 9005.21%. This contributed to the annual value of -$377.4 million for FY2024, which is 1295.04% up from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its EBT stood at $239.0 million for Q3 2025, which was up 31991.75% from -$35.4 million recorded in Q2 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' EBT peaked at $239.0 million during Q3 2025, and registered a low of -$405.9 million during Q3 2022.
  • Over the past 5 years, Alnylam Pharmaceuticals' median EBT value was -$188.3 million (recorded in 2021), while the average stood at -$138.3 million.
  • The largest annual percentage gain for Alnylam Pharmaceuticals' EBT in the last 5 years was 31991.75% (2025), contrasted with its biggest fall of 21662.94% (2025).
  • Alnylam Pharmaceuticals' EBT (Quarter) stood at -$260.3 million in 2021, then increased by 20.47% to -$207.0 million in 2022, then surged by 33.49% to -$137.7 million in 2023, then tumbled by 40.87% to -$194.0 million in 2024, then skyrocketed by 223.21% to $239.0 million in 2025.
  • Its EBT was $239.0 million in Q3 2025, compared to -$35.4 million in Q2 2025 and -$41.6 million in Q1 2025.